# Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct07055516` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07055516](<https://clinicaltrials.gov/study/NCT07055516>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07055516

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 176 participants.

## Technical summary

Registry record NCT07055516. Randomized; triple masking; primary purpose treatment. Start 2025-05-08 (actual); primary completion 2026-05-27 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 176 participants (enrolled count; ClinicalTrials.gov record NCT07055516, source copy `cardio:ctgov-nct07055516-2026-09-15`, retrieved 2026-11-18)
- Started: 2025-05-08 (actual) (ClinicalTrials.gov record NCT07055516, source copy `cardio:ctgov-nct07055516-2026-09-15`, retrieved 2026-11-18)
- Primary completion: 2026-05-27 (actual) (ClinicalTrials.gov record NCT07055516, source copy `cardio:ctgov-nct07055516-2026-09-15`, retrieved 2026-11-18)
- Completion: 2026-05-27 (actual) (ClinicalTrials.gov record NCT07055516, source copy `cardio:ctgov-nct07055516-2026-09-15`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT07055516, source copy `cardio:ctgov-nct07055516-2026-09-15`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07055516-2026-09-15`, retrieved 2026-11-18)

## The registry's words

- Brief title: Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes Mellitus
- Acronym: RESOLVE-1
- Condition: Obesity and Type 2 Diabetes
- Intervention (Drug): NT-0796
- Intervention (Drug): Placebo
- Lead sponsor: NodThera Ltd. (a Rezera company)
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: ff306ebfa918cc1526210884417570cd52927a7a4a334e599028d02351a62b62
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
